LinkMed carries out a secured rights issue of SEK 91.3 million

Press release 
May 7, 2009

LinkMed carries out a secured rights issue of SEK 91.3 million

• On May 7, 2009 LinkMed's Board of Directors resolved to carry out a new share
issue of SEK 91.3 million with preferential rights for shareholders. 
• The rights issue is fully secured by subscription undertakings, guarantee
commitments and declarations of intent by major LinkMed shareholders.
• Shareholders in LinkMed will receive five (5) subscription rights for each
share held on the record date of May 14, 2009, with six (6) subscription rights
entitling the holder to subscribe to one (1) new share.
• The subscription price is set at SEK 12.50 per share. 
• The subscription period is from May 19 to June 2, 2009.
• This rights issue will give LinkMed the opportunity to continue to assertively
develop its portfolio and take advantage of the favorable market situation,
enabling the company to complement its portfolio with interesting new
investments that support existing holdings.

Background and reasons

Investing in life science sector companies has been LinkMed's business concept
since it was founded in 1998. Today, LinkMed has a well-diversified portfolio
consisting of a wholly-owned subsidiary in the transplantation sector and eleven
associated companies, of which four are active in drug development and
biotechnology and seven in medical technology and diagnostics. 

Despite the ongoing dramatic economic developments in the world's financial
markets, LinkMed's portfolio continues to develop in the right direction and the
company's portfolio has now reached a level of maturity in which eight portfolio
companies already have or are expected to launch products on the market in 2009.

In 2008, LinkMed acquired the very profitable company Olerup SSP, which together
with AbSorber constitutes a strong platform in the highly interesting
transplantation sector. In the long-term, LinkMed aims to create a
well-positioned and profitable company by combining AbSorber and Olerup SSP.
This rights issue will provide LinkMed with the opportunity to create a common
sales organization and coordinate the resources of the two companies. 

LinkMed's associated companies BioResonator, Biovator, Likvor and Ortoviva all
have products that are close to market launch. LinkMed intends to support these
companies in their product launch to establish clear referral sales. It is
believed that this will enhance the potential of a higher valuation in the
future divestment of these companies. 

Furthermore, LinkMed has recently received a number of interesting proposals
from companies that are seeking new investors. As a result of the turbulence on
the world's financial markets, valuations in the life science sector are, from a
general point of view, low. This rights issue will enable LinkMed to act on
these proposals taking advantage of current market opportunities, of 
which LinkMed intends to prioritize complementing its existing portfolio
companies in the same manner as the combination of AbSorber and Olerup SSP.
Finally, the company will continue to monitor its investments in the drug
development sector.

In other respects, the Board of Directors refers to the prospectus for this
rights issue (in Swedish only) that is expected to be released around May 12,
2009.


Summary of terms and conditions

The shareholders in LinkMed have preferential rights to subscribe for new shares
in relation to the number of shares held on the record date. Each share in
LinkMed entitles the shareholder to five (5) subscription rights. Six (6)
subscription rights entitle the holder to subscribe with preferential rights to
one (1) new share. It will also be possible to subscribe to shares without
preferential rights. The record date for the rights issue is May 14, 2009.
Shareholders who are registered in the Shareholder Register held by Euroclear
Sweden AB (former VPC AB) on this date will receive subscription rights that
entitle them to participate in the rights issue. The subscription period will
extend from May 19 through June 2, 2009.

Three major LinkMed shareholders have undertaken to subscribe for shares from
the rights issue equivalent to their current pro rata shares in LinkMed,
equivalent to approximately 28.9 percent of the rights issue. These are
FastPartner AB (publ), Mannersons Fastighets AB and Mohammed Al Amoudi. In
addition, Länsförsäkringar småbolagsfond has shown support for the rights issue
by a declaration of intent to participate equivalent to its pro rata share of
approximately 5.0 percent of the rights issue. Furthermore, FastPartner AB
(publ) and Mohammed Al Amoudi have guaranteed to subscribe for remaining shares
equivalent to 66.1 percent of the rights issue. The rights issue is fully
secured by subscription undertakings, declarations of intent and guarantee
commitments. 

If the rights issue is not fully subscribed through subscription rights,
FastPartner AB (publ) and Mohammed Al Amoudi may at highest, following the
rights issue, as a result of guarantee commitments, have ownership stakes around
26.2 percent and 27.4 percent respectively of capital and votes in the company. 

The decision to carry out a rights issue is supported by the mandate given to
the Board of Directors by shareholders at the Annual General Meeting on April
22, 2009. 
Preliminary time schedule for the rights issue

May 12, 2009  First day of trading in the shares excluding the right to
participate in the rights issue

May 12, 2009  Anticipated prospectus publishing date.

May 14, 2009  Record date, meaning that shareholders who are registered in the
company's shareholder register on this date will receive subscription rights
that provide entitlement to participation in the rights issue.

May 19 - May 28, 2009  Trading in subscription rights.

May 19 - June 2, 2009  Subscription period

June 9, 2009  Release of the results of the rights issue.

Mid-July 2009  Rights issue is completed.


Financial and legal advisors
Swedbank Markets is LinkMed's financial advisor and Advokatfirman Lindahl is the
company's legal advisor.

For more information please contact:
Ingemar Lagerlöf, CEO, LinkMed: +46 8 508 939 93

Please visit LinkMed's website: www.linkmed.se

This press release contains such information that LinkMed is obliged to disclose
in accordance with the Swedish Financial Instruments Trading Act (1991:980) and
Swedish Securities Market Legislation (2007:528). This information was submitted
for publication at (approximately) 15:00 CET on May 7, 2009.


IMPORTANT INFORMATION

The information in this press release is not intended for distribution,
publication or disclosure, directly or indirectly, in or into the United States,
Canada, Australia, Hong Kong or Japan.
The information in this press release shall not be regarded as an offer to sell
shares or a request to acquire shares. Nor will any sale of the securities
referred to herein be permissible in any jurisdiction where such an offer,
request or sale would not be lawful without registration or applicable exemption
from registration pursuant to the securities legislation of such a jurisdiction.
A prospectus concerning the rights issue presented in this press release and the
subsequent listing of new shares on NASDAQ OMX Stockholm will be prepared and
submitted to the Swedish Financial Supervisory Authority for approval and
registration.

The information in this press release does not constitute an offering of LinkMed
securities in the U.S.; nor will the securities be offered or sold in the
absence of registration or exemption from registration pursuant to the American
Securities Act of 1933, as well as the rules and regulations under this act.
There is no intention of registering any part of an offering of LinkMed
securities in the US or of implementing a public offering of shares in the US.

The information in this press release may not be forwarded or distributed to any
third party; nor may it be reproduced in any manner. It is not permissible to
forward, distribute, reproduce or disclose this information, in full or in part.
Failure to observe these directives could constitute a breach of the American
Securities Act of 1933 or applicable laws in other jurisdictions.



LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management and capital, LinkMed has created a
portfolio of twelve companies, four in drug development and biotechnology and
eight in diagnostics and medical technology. The company's principal
shareholders are FastPartner, Koncentra Holding and the founder Ingemar
Lagerlöf. LinkMed is listed on the NASDAQ OMX Nordic Exchange in the Small Cap
section (ticker: LMED).